Partner Article
IDS acquires Italian company
Boldon-based drug testing company, Immunodiagnostic Systems Holdings PLC, has announced its acquisition of Italian company Diametra.
Diametra, based in Spello, Umbria, employs 25 staff and generated revenues of £2.65 million for the year ending 31 December 2013.
IDS has reportedly made the acquisition as part of a strategy to build its presence as a solution provider for speciality testing.
Prior to the acquisition, IDS and DIametra had been collaborating for 9 months.
The acquisition will now provide IDS with further development and manufacturing capabilities.
CEO of IDS, Patrik Dahlen, said: “ We are delighted to have secured the acquisition of Diametra, which will assist in the acceleration of our strategic plan outlined earlier this year.
“In particular, Diametra will provide immediate access to endocrinology manual assays in the area of steroid hormones that can be converted to automated assays for our iSYS instrument.
“We continue to pursue complementary acquisitions that will help us grow our specialist endocrinology menu and build operational excellence.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
Improving North East transport will improve lives
Unlocking investment potential before year end
Give us certainty to deliver better homes
Hormuz: Safe passage - not insurance - the issue
Don't get caught out by employment law change
When literacy thrives, our businesses thrive too
Building a more diverse construction sector
The value of using data like a Premier League club
Raising the bar to boost North East growth
Navigating the messy middle of business growth
We must make it easier to hire young people
Why community-based care is key to NHS' future